Audio

Community Oncology Podcast: T-DM1 in HER-2 positive breast cancer

Publish date: March 31, 2013

 

Editor-in-Chief Dr. David Henry highlights articles on T-DM1 for advanced HER2-positive breast cancer and an original research report from US Oncology on treatment patterns in women with HER2-/HR-positive breast cancer. He also looks at two case letters, one on plasmablastic lymphoma in the ileum, and a second on methotrexate-induced erythema multiforme, as well as a column by an oncology fellow on being a first-year fellow and first-year mom.

Recommended Reading

Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-negative breast cancer: NSABP protocol B-32
Breast Cancer ICYMI
A randomized, double-blind, placebo-controlled study of oral coenzyme Q 10 to relieve self-reported treatment-related fatigue in newly diagnosed patients with breast cancer
Breast Cancer ICYMI
Direct access to unexpected genetic test results
Breast Cancer ICYMI
Imaging agent approved for locating lymph nodes
Breast Cancer ICYMI
Lipid metabolism genes linked to breast cancer subtype
Breast Cancer ICYMI
Breast cancer: Cardiac risk increases with radiation dose to heart
Breast Cancer ICYMI
Contralateral prophylactic mastectomy adds complications
Breast Cancer ICYMI
Trastuzumab emtansine in advanced HER2-positive breast cancer
Breast Cancer ICYMI
Treatment patterns in HER2-/HR-positive postmenopausal women with metastatic breast cancer initiating first-line treatment in a community oncology setting in the US
Breast Cancer ICYMI
UPDATE ON BREAST HEALTH
Breast Cancer ICYMI